Related Experiment Video

Updated: May 24, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Interplay between heart and skeletal muscle disease in heart failure: the 2011 George E. Brown Memorial Lecture

Elizabeth M McNally1, Jeffery A Goldstein

  • 1Department of Medicine, University of Chicago, Chicago, IL 60637, USA. emcnally@uchicago.edu

Circulation Research
|March 3, 2012
PubMed

Insights

Genetic modifiers impact muscular dystrophy and cardiomyopathy progression. The transforming growth factor-beta pathway is crucial for heart and muscle dysfunction in these single gene disorders.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cardiology

Background:

  • Mutations in dystrophin-related genes cause muscular dystrophy and cardiomyopathy, leading to progressive muscle degeneration and cardiac dysfunction.
  • Disease presentation, including muscle weakness and cardiomyopathy onset, is highly variable even with identical mutations.
  • Investigating single gene disorders offers insights into complex human diseases.

Discussion:

  • This study utilized a mouse model to identify genetic loci modifying muscle pathology and cardiac fibrosis in muscular dystrophy and cardiomyopathy.
  • Distinct genetic modifiers were found for different muscle groups (diaphragm, abdominal, limb) and the heart.
  • A specific modifier gene highlighted the role of the transforming growth factor-beta pathway in disease pathogenesis.

Key Insights:

  • The transforming growth factor-beta (TGF-β) pathway is a significant contributor to heart and muscle dysfunction in muscular dystrophy and cardiomyopathy.
  • Canonical TGF-β signaling was confirmed to exacerbate heart and muscle problems using a Drosophila model.
  • Genetic sensitization models are valuable for uncovering pathways involved in complex diseases like heart failure and muscle weakness.

Outlook:

  • Further research into TGF-β signaling could reveal novel therapeutic targets for muscular dystrophy and cardiomyopathy.
  • Understanding genetic modifiers may lead to personalized treatment strategies for patients.
  • This work underscores the importance of exploring genetic modifiers in inherited diseases.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...